Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves an Updated Label for TRYVIO (aprocitentan) Removing the REMS Requirement
Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 09, 2025
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Idorsia Launches TRYVIO™ in the U.S. for Hard-to-Control Hypertension
Details : Tryvio (aprocitentan) is a first and only endothelin receptor antagonist, which is indicated for the treatment of hypertension in adult patients, in combination with other antihypertensive drugs.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2024
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
JERAYGO Recommended for Approval in Europe for Resistant Hypertension Treatment
Details : Jeraygo (aprocitentan), the first endothelin receptor antagonist, treats hypertension in adults by combining it with other antihypertensives to reduce blood pressure.
Product Name : Jeraygo
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 26, 2024
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
US FDA Approves Idorsia's TRYVIO As First Endothelin Antagonist for High Blood Pressure
Details : Tryvio (aprocitentan), an endothelin receptor antagonist, is indicated for treating hypertension when combined with other antihypertensives to lower blood pressure in adults.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 20, 2024
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : $343.0 million
Deal Type : Licensing Agreement
Idorsia Reacquires the World-Wide Rights to Aprocitentan
Details : Idorsia will reacquire the development and commercialization rights for aprocitentan, a potential novel, effective, once-daily, orally active, dual endothelin A and B receptor antagonist and well-tolerated treatment for resistant hypertension, from Janss...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 09, 2023
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : $343.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : JANSSEN BIOTECH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) is a dual endothelin receptor antagonist, which potently inhibits the binding of ET-1 to ETA and ETB receptors. It has a mechanism of action that is ideally suited for the pathophysiology of resistant hypertension.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 31, 2023
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : JANSSEN BIOTECH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan), is an investigational, novel, oral, dual endothelin receptor antagonist (ERA), which potently inhibits the binding of ET-1 to ETA and ETB receptors.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 20, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Aprocitentan (ACT-132577), a novel, dual ERA, which potently inhibits the binding of ET-1 to ETA and ETB receptors. Aprocitentan has a low potential for drug-drug interaction and a mechanism of action that is intended to address the pathophysiology of di...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 11, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Idorsia Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-132577 (aprocitentan) reduces blood pressure compared to placebo by week 4 of treatment, the effect is maintained and confirmed over a period of 48 weeks, and is generally well tolerated with no major safety concerns.
Product Name : Tryvio
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aprocitentan
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Study of Different Aprocitentan Tablet Formulations
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 19, 2022
Lead Product(s) : Aprocitentan
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable